Foghorn Therapeutics Inc. (FHTX) stock
FHTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.79−0.04 (-2.19%)
Close on Nov 18, 2026Market cap $106.30MP/E –Yield –
Foghorn Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Foghorn Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$84.29M. For fiscal 2025 it was -$86.15M. The highest annual figure on record is $192.40M in fiscal 2022.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$86.15M | – |
| FY2024 | Dec 31, 2024 | -$101.31M | – |
| FY2023 | Dec 31, 2023 | -$119.33M | -162.0% |
| FY2022 | Dec 31, 2022 | $192.40M | – |
| FY2021 | Dec 31, 2021 | -$53.56M | – |
| FY2020 | Dec 31, 2020 | -$47.47M | – |
| FY2019 | Dec 31, 2019 | -$47.30M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$17.89M | – |
| Q1 FY2026 | Mar 31, 2026 | -$25.27M | – |
| Q4 FY2025 | Dec 31, 2025 | -$22.27M | – |
| Q3 FY2025 | Sep 30, 2025 | -$18.86M | – |
| Q2 FY2025 | Jun 30, 2025 | -$21.02M | – |
| Q1 FY2025 | Mar 31, 2025 | -$24.00M | – |
| Q4 FY2024 | Dec 31, 2024 | -$25.00M | – |
| Q3 FY2024 | Sep 30, 2024 | -$21.31M | – |
| Q2 FY2024 | Jun 30, 2024 | -$25.55M | – |
| Q1 FY2024 | Mar 31, 2024 | -$29.45M | – |
| Q4 FY2023 | Dec 31, 2023 | -$27.58M | – |
| Q3 FY2023 | Sep 30, 2023 | -$27.29M | – |
| Q2 FY2023 | Jun 30, 2023 | -$32.64M | – |
| Q1 FY2023 | Mar 31, 2023 | -$31.82M | -111.7% |
| Q4 FY2022 | Dec 31, 2022 | -$29.19M | -347.4% |
| Q3 FY2022 | Sep 30, 2022 | -$20.32M | – |
| Q2 FY2022 | Jun 30, 2022 | -$29.38M | – |
| Q1 FY2022 | Mar 31, 2022 | $271.29M | – |
| Q4 FY2021 | Dec 31, 2021 | $11.80M | – |
| Q3 FY2021 | Sep 30, 2021 | -$20.73M | – |
| Q2 FY2021 | Jun 30, 2021 | -$19.69M | – |
| Q1 FY2021 | Mar 31, 2021 | -$24.94M | – |
| Q4 FY2020 | Dec 31, 2020 | -$18.14M | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.70M | – |
| Q2 FY2020 | Jun 30, 2020 | -$14.84M | – |
| Q1 FY2020 | Mar 31, 2020 | -$11.78M | – |
| Q4 FY2019 | Dec 31, 2019 | -$13.31M | – |
See a number that looks wrong?